rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
2008-1-8
|
pubmed:abstractText |
To evaluate the impact of the two most common CYP2C9 variant alleles (*2 and *3) on the maintenance dose of warfarin and on the quality of anticoagulation control in Brazilians.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1432-1041
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
64
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
9-15
|
pubmed:dateRevised |
2008-6-6
|
pubmed:meshHeading |
pubmed-meshheading:17955230-Adolescent,
pubmed-meshheading:17955230-Adult,
pubmed-meshheading:17955230-Aged,
pubmed-meshheading:17955230-Aged, 80 and over,
pubmed-meshheading:17955230-Alleles,
pubmed-meshheading:17955230-Anticoagulants,
pubmed-meshheading:17955230-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:17955230-Brazil,
pubmed-meshheading:17955230-Child,
pubmed-meshheading:17955230-Dose-Response Relationship, Drug,
pubmed-meshheading:17955230-Female,
pubmed-meshheading:17955230-Gene Frequency,
pubmed-meshheading:17955230-Genotype,
pubmed-meshheading:17955230-Hemorrhage,
pubmed-meshheading:17955230-Humans,
pubmed-meshheading:17955230-International Normalized Ratio,
pubmed-meshheading:17955230-Male,
pubmed-meshheading:17955230-Middle Aged,
pubmed-meshheading:17955230-Models, Genetic,
pubmed-meshheading:17955230-Odds Ratio,
pubmed-meshheading:17955230-Polymerase Chain Reaction,
pubmed-meshheading:17955230-Polymorphism, Restriction Fragment Length,
pubmed-meshheading:17955230-Risk,
pubmed-meshheading:17955230-Warfarin
|
pubmed:year |
2008
|
pubmed:articleTitle |
CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.
|
pubmed:affiliation |
Departamento de Medicina Clínica, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Rio de Janeiro, Brazil.
|
pubmed:publicationType |
Journal Article,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|